Emerging medical device maker Transcatheter Technologies GmbH unveiled an early look at clinical results for its 3rd-generation Trinity transcatheter aortic valve implantation platform, which the company calls "the world’s 1st ‘truly repositionable’ and, therefore, best TAVI system."
The pilot results included 4 female patients, all of whom had no paravalvular leak at 30 days and no need for new pacemakers, the German company reported.
"Unlike second-generation TAVI systems, the Trinity aortic valve was able to be positioned precisely or repositioned, even after full implantation, in a safe manner," principal investigator Dr. Christian Hengstenberg said in prepared remarks.
Transcatheter Tech. CEO Dr. Wolfgang Goetz, a cardiac surgeon by training, attributed the low rates of leakage and pacemaker implant to the Trinity implant’s ability to be moved even after full deployment.
"Once our valve is completely expanded and anchored above the annulus, a cardiologist can fully evaluate the valve’s function to determine whether it needs to be repositioned, retrieved, or kept in the same position," Goetz said in prepared remarks. "This feature is absolutely unique to Trinity, which is why we have positioned Trinity as a Third-Generation TAVI System."
The device maker is looking to make some waves in the TAVI world. Just last month Transcatheter Tech. announced its 1st-in-man implantation of the Trinity valve, treading into territory already marked by medtech giants such as Medtronic (NYSE:MDT) and St. Jude Medical (NYSE:STJ).